Park Capital Management LLC WI Invests $1.04 Million in Insmed, Inc. $INSM

Park Capital Management LLC WI acquired a new position in Insmed, Inc. (NASDAQ:INSM) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,989 shares of the biopharmaceutical company’s stock, valued at approximately $1,042,000. Insmed comprises approximately 0.7% of Park Capital Management LLC WI’s holdings, making the stock its 29th largest position.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. CIBC Private Wealth Group LLC increased its stake in shares of Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares during the last quarter. CoreCap Advisors LLC acquired a new position in Insmed during the fourth quarter worth $27,000. Stone House Investment Management LLC acquired a new position in Insmed during the third quarter worth $29,000. SBI Securities Co. Ltd. raised its holdings in Insmed by 404.9% during the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 166 shares in the last quarter. Finally, GraniteShares Advisors LLC bought a new position in shares of Insmed in the 4th quarter valued at approximately $30,000.

Insider Buying and Selling at Insmed

In related news, CFO Sara Bonstein sold 748 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $156.34, for a total value of $116,942.32. Following the sale, the chief financial officer owned 79,758 shares of the company’s stock, valued at $12,469,365.72. The trade was a 0.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Michael Alexander Smith sold 19,638 shares of the stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the completion of the transaction, the insider directly owned 51,871 shares of the company’s stock, valued at $7,831,483.58. This trade represents a 27.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 210,059 shares of company stock worth $33,702,709. Corporate insiders own 3.00% of the company’s stock.

Insmed Price Performance

Shares of INSM opened at $162.43 on Monday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The company has a 50-day simple moving average of $150.30 and a 200-day simple moving average of $166.82. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $212.75. The firm has a market capitalization of $35.06 billion, a P/E ratio of -25.34 and a beta of 1.10.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The firm had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The company’s revenue was up 152.6% on a year-over-year basis. During the same period last year, the company earned ($1.32) EPS. On average, equities research analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current year.

Analyst Ratings Changes

INSM has been the topic of several analyst reports. Wells Fargo & Company lowered their price target on Insmed from $208.00 to $175.00 and set an “overweight” rating on the stock in a report on Monday, March 23rd. Mizuho raised their target price on shares of Insmed from $204.00 to $206.00 and gave the company an “outperform” rating in a research note on Wednesday, March 25th. Cantor Fitzgerald boosted their target price on shares of Insmed from $216.00 to $230.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Morgan Stanley upgraded shares of Insmed from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $166.00 to $212.00 in a report on Monday, March 30th. Finally, Truist Financial set a $205.00 price objective on Insmed in a research note on Monday, January 12th. Three analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Insmed presently has an average rating of “Buy” and a consensus target price of $212.67.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.